Telix Pharmaceuticals (TLX) H1 2024 earnings summary

Executive summary

• Achieved strong commercial and operational progress in H1 2024, with 65% revenue growth to $364M, significant value creation across prostate, kidney, and brain cancer programs, and global expansion of Illuccix®.

• Positive data from prostate cancer therapy, expansion of global phase 3 Prostact study, and successful completion of key acquisitions (ARTMS, IsoTherapeutics, QSAM Biosciences) to enhance manufacturing and supply chain.

• Raised $650M in convertible bonds post-period, significantly strengthening the balance sheet and providing capacity for accelerated clinical development and strategic growth.

• Net profit after tax was $29.7M, a $44M improvement from a $14.3M loss in H1 2023.

• Gross margin increased to 66% from 63% in H1 2023, reflecting stable pricing and cost control.

Financial highlights

• Revenue grew 65% year-over-year to $364M, driven by Illuccix® U.S. sales.

• Gross margin improved to 66% (H1 2023: 63%).

• Adjusted EBITDA increased 66% to $57.5M (H1 2023: $34.7M).

• Operating profit from the commercial business rose 86% to AUD 175M, representing 49% of sales.

• Net operating cash flow was $39.1M (up from $13.3M in H1 2023); cash balance at 30 June 2024 was $118.8M.

Outlook and guidance

• Full-year revenue guidance set at US$490M–US$510M (A$745M–A$776M), a 48–54% increase on 2023.

• Focused on expanding prostate, renal, and brain cancer therapeutic and diagnostic products into pivotal trials and new markets.

• Anticipates regulatory approvals and launches for kidney and brain cancer diagnostics in the U.S., EU, UK, and Brazil in 2024–2025.

• R&D expenditure for 2024 expected to increase 40–50% over 2023, funded by commercial earnings.

• Convertible bond proceeds to fund label expansion, pivotal trials, and potential M&A.